These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25034748)

  • 21. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
    Al-Ali HK; Griesshammer M; le Coutre P; Waller CF; Liberati AM; Schafhausen P; Tavares R; Giraldo P; Foltz L; Raanani P; Gupta V; Tannir B; Ronco JP; Ghosh J; Martino B; Vannucchi AM
    Haematologica; 2016 Sep; 101(9):1065-73. PubMed ID: 27247324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
    Reilly JT; McMullin MF; Beer PA; Butt N; Conneally E; Duncombe AS; Green AR; Mikhaeel G; Gilleece MH; Knapper S; Mead AJ; Mesa RA; Sekhar M; Harrison CN
    Br J Haematol; 2014 Nov; 167(3):418-20. PubMed ID: 24961987
    [No Abstract]   [Full Text] [Related]  

  • 23. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
    Chen YH; Lee CH; Pei SN
    Leuk Lymphoma; 2015 May; 56(5):1528-9. PubMed ID: 25213182
    [No Abstract]   [Full Text] [Related]  

  • 24. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.
    Komatsu N; Kirito K; Shimoda K; Ishikawa T; Ohishi K; Ohyashiki K; Takahashi N; Okada H; Amagasaki T; Yonezu T; Akashi K
    Int J Hematol; 2017 Mar; 105(3):309-317. PubMed ID: 27832516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review.
    Bucelli C; Cattaneo D; Valli VB; Levati GV; Lonati S; Gianelli U; Iurlo A
    Chemotherapy; 2018; 63(6):340-344. PubMed ID: 30965327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
    Koschmieder S; Jost E; Cornelissen C; Müller T; Schulze-Hagen M; Bickenbach J; Marx G; Kleines M; Marx N; Brümmendorf TH; Dreher M
    Eur J Haematol; 2020 Nov; 105(5):655-658. PubMed ID: 32593209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
    Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
    Aylı M; Özcan M; Cengiz Seval G
    Turk J Haematol; 2015 Jun; 32(2):180-3. PubMed ID: 26316489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.
    Wade R; Rose M; Neilson AR; Stirk L; Rodriguez-Lopez R; Bowen D; Craig D; Woolacott N
    Pharmacoeconomics; 2013 Oct; 31(10):841-52. PubMed ID: 23996108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.
    Saeed I; McLornan D; Harrison CN
    Expert Rev Hematol; 2017 Jul; 10(7):617-625. PubMed ID: 28571503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.
    Talpaz M; Erickson-Viitanen S; Hou K; Hamburg S; Baer MR
    J Hematol Oncol; 2018 Aug; 11(1):101. PubMed ID: 30086777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ruxolitinib: a new treatment option for myelofibrosis.
    Ganetsky A
    Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case.
    Sugiura H; Nishimori H; Nishii K; Toji T; Fujii K; Fujii N; Matsuoka KI; Nakata K; Kiura K; Maeda Y
    Intern Med; 2020 Aug; 59(16):2023-2028. PubMed ID: 32448830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical management of myelofibrosis with ruxolitinib.
    Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
    Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis.
    Maccaferri M; Leonardi G; Marasca R; Colaci E; Paolini A; Soci F; Forghieri F; Potenza L; Narni F; Luppi M
    Leuk Lymphoma; 2014 Sep; 55(9):2207-8. PubMed ID: 24354678
    [No Abstract]   [Full Text] [Related]  

  • 38. Ruxolitinib.
    Becker H; Engelhardt M; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.
    Marchetti M; Barosi G; Cervantes F; Birgegård G; Griesshammer M; Harrison C; Hehlmann R; Kiladjian JJ; Kröger N; McMullin MF; Passamonti F; Vannucchi A; Barbui T
    Leukemia; 2017 Apr; 31(4):882-888. PubMed ID: 27740634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
    Deisseroth A; Kaminskas E; Grillo J; Chen W; Saber H; Lu HL; Rothmann MD; Brar S; Wang J; Garnett C; Bullock J; Burke LB; Rahman A; Sridhara R; Farrell A; Pazdur R
    Clin Cancer Res; 2012 Jun; 18(12):3212-7. PubMed ID: 22544377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.